Category Archives: Pharmacogenomics

Molecular Diagnostics Market is worth USD 5.44 billion in 2014 and is expected to reach USD 11.04 billion by 2022, at a CAGR of 9.3% from 2014 to 2022.

The global molecular diagnostics market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the molecular diagnostics market.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10325645

KEY BENEFITS OF THE REPORT:Extensive evaluation of all the market dynamics that will impact this market during the forecast periodGranular understanding of the historical market trend and the resultant market forecastDeeper understanding of the behavior of the key players and innovators influencing this market

KEY PREMIUM INDUSTRY INSIGHTS:Growing prevalence of chronic diseases, the increased usage of the biomarkers, high demand for the personalized medicines, and the rapid technology advancements are the major drivers for the molecular diagnostics market.

According to the World Health Organization, by 2020, chronic diseases are estimated to account for around 58% of the global burden of disease and 60% of this burden will occur in the emerging countries. The governments are keen on controlling and preventing these diseases by putting greater emphasis on preventive health solutions and personalized care.

Various advancements in precise detection and diagnoses of disease will help reduce the cost of treating these chronic conditions. The molecular diagnostics market is set to increase exponentially in the future.

Molecular diagnostics techniques lead to the development of the advanced diagnostics and blood screening platforms and tests. They also help to develop a better understanding of the nature of chronic diseases and devise pathways to develop personalized treatments.However, the regulatory landscape and reimbursement issue are the major restraints for the global market.

Applications of molecular diagnostics in cancer management and pharmacogenomics will present the major opportunities for this market. The shift in technology such as point of care will further boost this market.

MARKET SEGMENTATION:This report analyzes the molecular diagnostics market by the following segments:

Molecular Diagnostics Market, by ProductsReagents and ConsumablesInstruments and SystemsMolecular Diagnostics Market, by TechnologiesPolymerase Chain Reaction (PCR)Immunochemical TechnologiesMicroarraysSequencingIsothermal Nucleic Acid Amplification Technology (INAAT)Other TechnologiesMolecular Diagnostics Market, by ApplicationsInfectious DiseasesOncologyGenetic Screening and TestingBlood ScreeningMicrobiologyOther Applications

Request For Full Report:https://www.kennethresearch.com/sample-request-10325645

KEY MARKET PLAYERS:Key players in the molecular diagnostics market include:

AbbottDanaher CorporationBecton, Dickinson and CompanyBioMerieux S.A.Grifols International, S.A.Hologic Inc.Qiagen N.V.F. Hoffmann-La Roche AGSiemens AGSysmex Corporation

<<<<>>>>Cloud Infrastructure Market Smart Cities Market IoT MarketLED MarketSmart Grid MarketVirtual Reality MarketAugmented Reality Market

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

More here:
Molecular Diagnostics Market Growth Forecast and Segmentation based on Industry-wise 2022 - The Daily Chronicle

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind, the leader in comprehensive genetics and digital mental health services, has pioneered a new level of specificity and accuracy for cheek swab-based pharmacogenetics tests.

Genominds Professional PGx Express test provides clinicians with a comprehensive report of up to 24 genes that delivers important prescribing guidance designed to help reduce the traditional process of trial and error with mental health medications. Genomind has served over 15,000 clinicians and tested over 270,000 patients for this important treatment guidance. The FDA includes pharmacogenetic biomarker warnings, precautions and drug-drug interaction guidance on the labels of over 270 medications (https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling).

Two of the most important genetic variants which Genominds Professional PGx Express tests for are HLA-B *15:02 and HLA-A*31:01. These genes are part of the complex human leukocyte antigen (HLA) system that is among the most highly variable DNA regions in humans and is central to autoimmune diseases and transplant rejection. Both of these variants are associated with an increased risk of serious, sometimes fatal, skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, in the presence of carbamazepine (as well as oxcarbazepine and phenytoin for HLA-B*15:02).

Carbamazepine is indicated for the treatment of epilepsy and trigeminal neuralgia, and is commonly used for individuals with mood disorders, such as bipolar disorder. It is on the World Health Organizations List of Essential Medicines1 and was prescribed over 3.5 million times in 2019, a number that experts say will increase in 20202.

In contrast to HLA-B*15:02, the HLA-A* 31:01 allele is more common in Caucasians, while also occurring in individuals of Hispanic/South American and East Asian descent. Carbamazepines FDA label contains warnings about this gene-drug pair, as does the Clinical Pharmacogenetic Implementation Consortium (CPIC).

Until recently, commercial PGx assays commonly tested for this allele using a surrogate tag SNP (single nucleotide polymorphism) method. During a recent validation exercise, Genomind identified a very high false positive rate of approximately 40%, with this common industry method. This means with the traditional testing method, 40% of the positive tests would incorrectly identify someone as being at risk of serious adverse events with carbamazepine treatment, thereby inappropriately excluding a potentially useful agent.

Genominds CEO Shawn OBrien was inspired to find a better solution. Our company is all about our I-CAIRE culture (integrity, collaboration, accountability, innovation, respect and excellence), so when we discovered this shortcoming in the industry, we immediately set about finding a better solution to help more clinicians and patients.

Genomind scientists, led by CSO Dr. David Robbins, developed an innovative and proprietary real-time PCR (polymerase chain reaction) test that is highly specific for HLA-A*31:01. The increased specificity of this assay also makes the need for confirmatory testing unnecessary for individuals testing positive. In validation testing of this new and improved assay, specificity and sensitivity were 100%. In real-world testing we expect specificity to be >99%. This means we will be able to reduce the 40% of false positives down to a fraction of a percentage3. This PCR-based testing was validated by comparing random anonymized patient samples with HLA typing by Next Generation Sequencing (NGS) through a third party lab. FDA considers NGS as the gold standard for HLA typing. The validation was further supported by testing samples from the Coriell Institute for Medical Research with documented rare and common HLA-A types. Genomind filed a patent on this important breakthrough and is the only comprehensive mental health genetics test with this capability on the market.

This novel innovation uniquely provides much greater accuracy in identifying patients at risk for a serious drug reaction and provides greater and safer access of a potentially helpful medication, carbamazepine, for individuals previously thought to be at risk said Dr. Scott Aaronson, MD, Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and Distinguished Fellow of the American Psychiatric Association.

With Medicares recently published new Local Coverage Determination allowing coverage of tests like Genominds, and with United Healthcares positive coverage policy, the Mental Health PGx industry is expected to see major growth. Therefore, it is critical that clinicians have access to the most accurate and specific PGx results.

To this end Genomind is offering a major national digital education effort for clinicians and patients. They are starting with their 15,000 clinicians and providing education materials, access to their acclaimed On-Demand Hotline or scheduled consults, and free access to their state-of-the-art precision medication management software, G-DIG (Genomind Drug Interaction Guide.) Genomind will also be reaching tens of thousands of the highest prescribers of mental health medications and millions of potential patients with their digital communications engine that generates millions of hits and video views on their website annually. Genomind is offering all their advanced services and software to any new registering clinician.

About Genomind

Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind Professional PGx Express, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients mental health treatment. The Company also recently launched Genomind Mental Health Map a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at http://www.genomind.com.

(1) World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

(2) "Carbamazepine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

(3) This fraction of a percent represents the real world use HLA-A*31 types other than 31:01 (ie. HLA-A*31:04, 31:12, and 31:16) which may rarely cause false positive results. That being said, it is not known if these types are associated with skin disorders following use of carbamazepine.

Read more from the original source:
Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for...

About the author:Dr. Liz Kwo is currently the staff VP of clinical data analytics at Anthem, and previously cofounded and served as CEO of telemedicine second opinion company InfiniteMD. She received anMDfrom Harvard Medical, an MBA from Harvard Business School and an MPH from the Harvard T.H. Chan School of Public Health.

COVID-19 has reshaped the way humans interact with technology in healthcare. Many countries have responded with public health measures such as social distancing, masks, and quarantine for suspected and confirmed cases.Intelligent data, technology, artificial intelligence (AI)and machine learning (ML) havestarted to lighten the burden to establish new ways for both health system supply and demand sustainability.

Among the most visible promoters of digital health arenext-generation payers and providers (NGPPs). These companies, many of them created after implementation of the Affordable Care Act (ACA), have commonly adopted the belief that technology is the solution to improving the healthcare system. Their focus is on delivering technology-enabled solutions to improve clients, such as employers' but more importantly, patients' as the end-user's experiences. These companies are using concepts such as blockchain, telehealth, web applications and genomics.

COVID-19 has prompted more healthcare organizations to embrace the idea of intelligent data as a tool for migration to digital health. Several companies are teaming up with startups that have the means to deliver technology-enhanced solutions either by allowing these startups to connect to their systems or by creating a customer-vendor type of relationship.

Connecting a smaller startup to a healthcare companys mainframe or command center means the startup involved in the process must codevelop solutions customized to the systems processes, flows, infrastructure and objectives. By accessing the companys platforms, whether a payor or provider through an electronic health record (EHR), a customer relationship management(CRM) system or other approach, the startup provides valid solutions based on the current status.

The solutions are not limited to identifying problems and providing fixes, but must extend to presenting innovations that enable the company to improve their patient records, deal more efficiently with aggregated and dispersed data, and handle a larger amount of information collected from various sources.

For example, collecting data run through predictive analytics via biometric devices that are connected remotely enables clinicians to complete their tasks at a higher speed with increased accuracy if the insights are actionable, potentially reducing medical costs if treatment or interventions can be determined correctly that arecustomized to the patient.

However, the downside of this type of cooperation is that it requires mobilization of massive internal resources, a relationship built on mutual trust and the willingness to share the risk among stakeholders such as providers, technology-enablement service companiesand payors. Therefore, health companies look to startup companiesfor innovative solutions that can be easily integrated in their workflows with ready-to-implement solutions, such as technology enabling remote consults between patients and care providers.

AI, for instance, requires multiple levels of mutual agreement between the healthcare companies and collaborative startups for processes such as data sharing privacy and security, liability protections, validation of models, and ongoing monitoring of progress and milestones. The implementation of AI in clinics has specific requirements, such as the availability of a workforce trained to use digital tools, remote access to the latest technologies, and knowledge and willingness from both clinicians and patients to adopt these tools.

AI has produced valuable techniques that are in place and will continue to improve in triaging care via chatbots, models for data integration that enable a better and faster illness prognosis, predicting illness progression through medical records, and detecting anomalies for fraud prevention in claims or to ensure proper claims payments.

Blockchain provides a change of secure and accurate information between nodes (e.g. patients, organizations andclinicians) with the help of a databasethat doesnt require control from a third party. Blockchain enables organizations to conduct trusted transactions and to reduce their administrative costs by sharing a common ledger instead of maintaining their own, separate data.

All the organizations participating in the blockchain have access to the shared data and can instantly protect it if accessed by unauthorized users. In the healthcare sector, blockchain is still in the early stages, and faces challenges such as the network effect, meaning that all parties sharing the blockchain must be willing to work together in testing and evaluating the advantages of this technology, which is easier said than done.

Deploying blockchain for provider access can mean that patients who are not able to find a doctor in their network can have access to a wider pool of physicians, hence benefiting from faster and improved access to care.

Telehealth (also referred to as e-health, mobile-healthor telemedicine) represents a means to remotely access medical services with the help of digital technologies such as laptops, smartphones and any mobile devices.

Among the objectives of telemedicine:

Examples of what telehealth can provide include:

Telehealth was used before COVID-19 in various formsas an instrument to train doctors in treating complex diseases in rural areas via video conference, such as the partnership between Medicaid and Extension for Community Healthcare Outcomes (ECHO) put in place at the University of Mexico,or as remote consultations with the use of symptom checkers defined by user inputs adopted in Spain by Mediktor.

COVID-19 brought a huge increase in Telehealth adoption. In the U.S., telehealth became used by 45% of consumers in COVID-19 era, compared to 11% of consumers in 2019 that called on this method to replace healthcare trips to the doctors office. Before the pandemic, the main players in the U.S. telehealth sector focused their services on urgent care areas by providing patients telehealth visits on demand. If before COVID-19 the estimated yearly revenues of U.S. telehealth companies were $3 billion, its estimated that in the next years up to $250 billion of current U.S. healthcare market could be invested in the virtualization of medical assistance through telehealth.

Telehealth, however, has its own challenges. Providers will need to adopt new ways of working;the exchange of concise and useful information must be improved;wider access and integration of technology is required;and clear data security measures must be in place. The effectiveness of telehealth compared to in-person visits will be closely measured, and reimbursement policies will have to be established and implemented properly.

For patients, the awareness and education of telehealth benefits must be understood, such as specific use cases to transmit valid information, the medical needs that telehealth can address, and understanding the insurance coverage of the service. These challenges can be surmounted, considering telehealth has the potential to bring benefits for patients, decrease costs for payers, increase efficiency for medical staffandimprove overall healthcare experience.

Web applications were developed as a response to the consumers expectations to have instant access to information. The healthcare market is currently dominated by two types of applications: ones that collect and record data regarding the health of clients (that can be shared with care providers and health insurance companies) and applications that provide access to health-related information such as health and wellness programs or provider and medical recommendations.

Mobile applications provided by some health insurance companies offer clients the opportunity to become more engaged in building their own team of healthcare providers, in order to compare prices of various services and to have autonomy in their overall health. With a few clicks, patients can locate providers inside and outside their network, choose an emergency room or urgent care center they need, or find a specialist that is available with a next-day appointment.

Many applications are populated with a huge database that delivers enormous amounts of informationin multiple languageson topics such as diseases, symptomsand medications, and are reviewed by prestigious medical professionals. Other applications are focused on prevention, helping people maintain good health by focusing them on behaviors such as motivational exercise or mindful eating, as in controlling consumption by documenting the foods they intend to eat and the impact on their health. They can calculate the caloric intake and compare foods to make better decisions.

Aside from the benefits brought to patients, web applications help providers collaborate with their patients. Applications that measure and monitor patient heart rates and blood sugar levels are equipped with triggers that send alerts when indicators reach a certain level. The alert is sent to the doctors that monitor those clients. Based on the reading and the medical history,the doctors can suggest a next step. As more people adopt these web applications, the tools will only become easier and faster to use as they improve over time.

The human genome, considered the blueprint of the human body, holds the potential biological plan for each individual. The link between a typical genome versus variants that may lead to disease can be established by analyzing a huge amount of medical records and genetic data. This is a complex, time-consumingmatching process.

The combined use of AI, machine learningand genomics brings to healthcare what has been missing in this discovery process: simplification and more accurate results in a lot shorter period of time. This can be achieved by integrating, for example, genomics with lab results, EHRs that include pathology, and imaging. T

This integration provides a more comprehensive look into a patient, which translates into better decisions taken by a supervising doctor andthe improved ability to forecast disease and to provide customized treatment and medication based on prediction patterns and the efficacy of a medication for the individual. By improving the ability to predict and treat, the costs of healthcare can be reduced by eliminating unnecessary lab tests or ineffective treatments.

The challenge in utilizing genomic data is translating this knowledge to real-world use cases. Pharmacogenomics is the use of genetic testing to inform medication-management decisions, which can improve patient outcomes and reduce health cost. For example, genomic data is used to determine treatment options for cancer patients.

This type of precision medicine creates a new consumer healthcare market for people to determine the influencing factors of their health, with extraordinary levels of treatment personalization across various chronic conditions. As patients ask their providers for advice and payers for coverage in this growing market, providers will need clear training to understand the right tests to order, how to interpret the results, and how to properly inform their patients about the results.

The costs of these tests have significantly decreased over time, but an adequate understanding of the benefits is required to achieve actionable insights from the results.

The progress made in intelligent data and AI use in the healthcare sector is surging. It is vital to ensure that all patients have access and affordable healthcare utilizing efficient tools and customized treatments that rely on intelligent data for groundbreaking innovations in healthcare.

Link:
How intelligent data transforms health in the time of COVID-19 - Mobihealth News

Global gene expression analysis market was valued US$ 4.2 Bn in 2017 and is expected to reach US$ 8.6 Bn by 2026, at a CAGR of 9.37 % during a forecast period.

Gene expression is a procedure of deriving information from a gene to synthesize a functional gene product. Rising use of gene expression analysis in precision medicine provides key opportunities for the market during the forecast period.

Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/6087

Falling cost of sequencing, technological advancements, increasing the prevalence of cancer, and availability of government funding are propelling the market growth. Novel technologies to aid gene expression studies, rising application areas of gene expression, and availability of gene expression databases are boosting the growth the global gene expression analysis market. Currency Devaluation is a major challenge of the market. The high cost of instruments and lack of trained professionals are hindering the market growth.

The growing volume of genetic tests in drug & biomarker discovery and pharmacogenomics applications are driving the growth of the consumables market. The rising installation of NGS & PCR tools worldwide will significantly boost the demand for consumables. PCR analysis is estimated to the largest revenue share owing to high adoption & introduction of systems integrated with other steps as well as techniques.

Pharmaceutical & biotechnology companies utilize gene expression analysis products & services to achieve their clinical research goals like drug discovery & development and biotech research. The high volume of research studies involving gene expression analysis and huge capital for high-end analysis instruments & consumables is expected to grow at the highest rate during the forecast period in the pharmaceutical and biotechnology segment.

The Asia Pacific market is expected to grow at the highest rate during the forecast period owing to the domestic manufacturing of sequencing systems, western partnerships to improve healthcare, high R&D intensity, government focus on cancer and other life science research, and flourishing bioresearch centers.

Key player operating in global gene expression analysis market are Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffmann-La Roche, GE Healthcare, Illumina, Inc., Oxford Gene Technology, Pacific Biosciences of California, Inc., Perkinelmer, Inc., Qiagen N.V., and Thermo Fisher Scientific, Inc.

The Scope of Global Gene Expression Analysis Market:

Global Gene Expression Analysis Market, by Products & Services:

Consumables

Instruments

Services

Global Gene Expression Analysis Market, by End User:

Pharmaceutical & Biotech companies

Academic Institutes & Research Centers

Other End User

Global Gene Expression Analysis Market, by Region:

North America

Europe

Asia Pacific

South America

Middle East & Africa

Key Player Operating in Global Gene Expression Analysis Market:

Agena Bioscience

Applied Microarrays

Arrayit

AutoGenomics

BD

Beijing Genomics Institute

BioChain Institute

Biometrix Technology

Cepheid

CombiMatrix

Danaher

Danyel Biotech

EMD Millipore

Eppendorf

Exiqon

Fluidigm

GE Healthcare

Great Basin

LC Sciences

Luminex

Microarrays

Miltenyi Biotec

OriGene Technologies

Oxford Gene Technology

Oxford Nanopore Technologies

Partek

Perkin Elmer

Phalanx Biotech Group

Promega

Takara Bio

Tecan

Veredus Laboratories

Zyagen.

More Info of Impact COVID-19@https://www.trendsmarketresearch.com/report/covid-19-analysis/6087

Read the original post:
Gene Expression Analysis Market to Surge at a Robust Pace in Terms of Revenue over COVID-19 Crisis 2018 2026 - Kentucky Journal 24

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Pharmacogenomics Market market.

Trusted Business Insights presents an updated and Latest Study on Pharmacogenomics Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Pharmacogenomics Market market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Pharmacogenomics Market 2020 (Includes Business Impact of COVID-19)

Global Pharmacogenomics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global pharmacogenomics market report has been segmented on the basis of technology, application, end user, and region.

Request Covid 19 Impact

Global Pharmacogenomics Market: Overview

Pharmacogenomics is a branch of genetics which is concerned with determining the response of an individual to particular drugs. It is a combination of pharmacology -the science of drugs and genomics which means the study of genes and their functions. Pharmacogenomics techniques are used for the development of effective and safe medications with specific genetic makeup.

Global Pharmacogenomics Market: Dynamics

Rising incidences of chronic diseases such as tuberculosis, cancer, HIV, and many others is a major factor anticipated to drive the growth of the global pharmacogenomics market over the forecast years. In addition, increasing number of geriatric population, higher adoption rate of pharmacogenomics procedure by the various healthcare professionals, and growing demand for personalized therapy are some of the other factors expected to drive revenue growth of the target market. Furthermore, higher health care expenditure and increasing incidences of lifestyle diseases are some among another factors expected to boost the demand for pharmacogenomics. However, high cost associated with test and lack of technical expertise and trained professional in developing and under developing countries are some of the major factors that may hamper the growth of target market to a significant extent.

Global Pharmacogenomics Market: Segment Analysis

Among the technology segments, polymerase chain reaction segment is expected to register the highest market share in terms of revenue as compared to other technologies. This is due to, increasing usage of PCR for in molecular biology for making many copies of a specific DNA segment and is very quick and accurate technique, resulting in higher adoption rate. Among the application segments, oncology is expected to anticipate highest market revenue share over the forecast period, owing to growing demand for the use of pharmacogenomics advent technologies in drug discovery and development for oncology treatment. Among the end user, hospitals and clinics are expected to account for significant share as compared to other end user segment. This can be due to, the presence of highly skilled and expects medical professionals with better infrastructure and advance technologies.

Global Pharmacogenomics Market: Trend

Major players are investing high amount for researcher activity in order to study the safety and efficiency of drugs. In addition, prominent manufacturers are collaborating with other research institute for carrying out clinical pharmacogenomics testing. Also, the government are funding companies that work for development of bioinformatics technology for precision medicine research applications. The above mentioned are among some of the key trends observed in the global pharmacogenomics market.

Global Pharmacogenomics Market: Regional Analysis

In 2019, the markets in North America is projected to a significant market share over the forecast period. This is primarily due to, presence of developed medical facilities and healthcare sector, increasing incidences of chronic diseases, and high patient awareness level in countries in the region. The market in the Asia Pacific is projected to register fastest growth rate over the forthcoming years. This can be primarily attributed to, increasing preference among patients for personalized treatment, increasing number of clinical trials as well as research and development activates in countries of Asia Pacific region.

Global Pharmacogenomics Market Segmentation:

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthers

Segmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthers

Segmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

Looking for more? Check out our repository for all available reports on Pharmacogenomics Market in related sectors.

Quick Read Table of Contents of this Report @ Global Pharmacogenomics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

The rest is here:
Global Pharmacogenomics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2028 - The Scarlet

Transparency Market Research (TMR) has published a new report titled, Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027.

Overview

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10235

New Born Screening Segment to Dominate Global Genetic Testing Services Market

Request for Analysis of COVID19 Impact on Genetic Testing Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10235

Oncology Segment Hold a Major Share of Global Genetic Testing Services Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=10235

Hospitals based laboratories Segment to Dominate Global Genetic Testing Services Market

North America to Dominate Global Genetic Testing Services Market

Buy Genetic Testing Services Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=10235&ltype=S

Competitive Landscape

The global genetic testing services market is consolidated in terms of number of players. Key players in the global Genetic Testing Services market include Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Genomic Health, Inc., NeoGenomics Laboratories, Inc, Eurofins Scientific, Ambry Genetics, Illumina, Inc, 23andMe, Inc., Exact Sciences, Natera, Invitae, Veracyte, and other prominent players.

Browse More Trending Reports by Transparency Market Research:

Nitinol Stents Market: https://www.transparencymarketresearch.com/nitinol-stents-market.html

Neurology Sterile Injectable Market: https://www.transparencymarketresearch.com/neurology-sterile-injectable-market.html

Microplate Systems Market: https://www.transparencymarketresearch.com/microplate-systems-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the rest here:
Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market - BioSpace